Testing the ubiquitin–proteasome hypothesis of neurodegeneration in vivo

Glickman, 2002, The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction, Physiol. Rev., 82, 373, 10.1152/physrev.00027.2001 Lindsten, 2003, A transgenic mouse model of the ubiquitin/proteasome system, Nat. Biotechnol., 21, 897, 10.1038/nbt851 Hershko, 1998, The ubiquitin system, Annu. Rev. Biochem., 67, 425, 10.1146/annurev.biochem.67.1.425 Schwartz, 1999, The ubiquitin–proteasome pathway and pathogenesis of human diseases, Annu. Rev. Med., 50, 57, 10.1146/annurev.med.50.1.57 Sherman, 2001, Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases, Neuron, 29, 15, 10.1016/S0896-6273(01)00177-5 Goedert, 1998, Filamentous nerve cell inclusions in neurodegenerative diseases, Curr. Opin. Neurobiol., 8, 619, 10.1016/S0959-4388(98)80090-1 Kitada, 1998, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392, 605, 10.1038/33416 Leroy, 1998, The ubiquitin pathway in Parkinson's disease, Nature, 395, 451, 10.1038/26652 Liu, 2002, The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility, Cell, 111, 209, 10.1016/S0092-8674(02)01012-7 Keller, 2000, Impaired proteasome function in Alzheimer's disease, J. Neurochem., 75, 436, 10.1046/j.1471-4159.2000.0750436.x McNaught, 2001, Proteasomal function is impaired in substantia nigra in Parkinson's disease, Neurosci. Lett., 297, 191, 10.1016/S0304-3940(00)01701-8 Dı́az-Hernández, M. et al. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. (in press). Bence, 2001, Impairment of the ubiquitin–proteasome system by protein aggregation, Science, 292, 1552, 10.1126/science.292.5521.1552 Ding, 2002, Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival, J. Biol. Chem., 277, 13935, 10.1074/jbc.M107706200 Jana, 2001, Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release, Hum. Mol. Genet., 10, 1049, 10.1093/hmg/10.10.1049 Nishitoh, 2002, ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats, Genes Dev., 16, 1345, 10.1101/gad.992302 McGuire, 1989, The high molecular weight multicatalytic proteinase, macropain, exists in a latent form in human erythrocytes, Biochim. Biophys. Acta, 995, 181, 10.1016/0167-4838(89)90078-2 Kisselev, 2002, Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings, J. Biol. Chem., 277, 22260, 10.1074/jbc.M112360200 Voges, 1999, The 26S proteasome: a molecular machine designed for controlled proteolysis, Annu. Rev. Biochem., 68, 1015, 10.1146/annurev.biochem.68.1.1015 Dantuma, 2000, Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells, Nat. Biotechnol., 18, 538, 10.1038/75406 Stack, 2000, A ubiquitin-based tagging system for controlled modulation of protein stability, Nat. Biotechnol., 18, 1298, 10.1038/82422 Illing, 2002, A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system, J. Biol. Chem., 277, 34150, 10.1074/jbc.M204955200 Petrucelli, 2002, Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons, Neuron, 36, 1007, 10.1016/S0896-6273(02)01125-X Verhoef, 2002, Aggregate formation inhibits proteasomal degradation of polyglutamine proteins, Hum. Mol. Genet., 11, 2689, 10.1093/hmg/11.22.2689 Saudou, 1998, Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions, Cell, 95, 55, 10.1016/S0092-8674(00)81782-1 Martin-Aparicio, 2001, Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease, J. Neurosci., 21, 8772, 10.1523/JNEUROSCI.21-22-08772.2001 Guidetti, 2001, Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production, Exp. Neurol., 169, 340, 10.1006/exnr.2000.7626 Hansson, 1999, Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity, Proc. Natl. Acad. Sci. U. S. A., 96, 8727, 10.1073/pnas.96.15.8727 Wong, 2002, Genetically engineered mouse models of neurodegenerative diseases, Nat. Neurosci., 5, 633, 10.1038/nn0702-633 Rubinsztein, 2002, Lessons from animal models of Huntington's disease, Trends Genet., 18, 202, 10.1016/S0168-9525(01)02625-7 Kisselev, 2001, Proteasome inhibitors: from research tools to drug candidates, Chem. Biol., 8, 739, 10.1016/S1074-5521(01)00056-4 Lindsten, 2002, Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation, J. Cell Biol., 157, 417, 10.1083/jcb.200111034 Johnson, 1995, A proteolytic pathway that recognizes ubiquitin as a degradation signal, J. Biol. Chem., 270, 17442, 10.1074/jbc.270.29.17442